Dose-dependent efficacy and safety of rosuvastatin in dyslipidemia patients at high risk for cardiovascular diseases

Objective To evaluate the dose-dependent efficacy and safety of rosuvastatin in dyslipidemia patients at high risk for cardiovascular diseases.Methods 51 dyslipidemia patients at high risk for cardiovascular diseases were all administrated rosuvastatin 10mg per day orally.The patients who reached the target level defined by ATP III after 8 weeks were randomly divided into two groups,of which rosuvastatin 10mg per day(group A) in 19 cases and rosuvastatin 5mg per day(group B) in 18 cases.The lipidlowing efficacy and adverse events were compared after another 8 weeks.Results After 4 weeks,LDL-C reduced 27.72,the target LDL-C goal rate 52.94.After 8 weeks,LDL-C reduced 37.52,the target LDL-C goal rate 72.55,meanwhile HDL-C increased 2.89.Compared with group A,LDL-C in group B rose significantly(2.13 ± 0.35 vs 2.93 ± 0.36mmol/L,P 0.05),but the target LDL-C goal rate decreased significantly(89.47 vs 38.89,P 0.01).The difference between two groups was statistically significant.It was difficult to sustain the ATP III target level with rosuvastatin 5mg per day.There were no drug-related serious adverse events during the study.Conclusions It is showed that,rosuvastatin 10mg per day,not 5mg per day,significantly and sustainably reduced LDL-C and TC,increasing HDL-C at the same time,both with good safety and tolerance in the high-risk dyslipidemia patients.